HebertAA.SiegfriedEC.DurhamTet al. Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: A randomized clinical trial. J Am Acad Dermatol. 2020;82(4):887-894doi:10.1016/j.jaad.2019.09.064http://www.ncbi.nlm.nih.gov/pubmed/31586600
2.
van der WoudenJC.van der SandeR.KruithofEJet al. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev. 2017;5(4):CD004767.doi:10.1002/14651858.CD004767.pub4http://www.ncbi.nlm.nih.gov/pubmed/28513067
3.
BanerjeeNS.MooreDW.WangH-K.BrokerTR.ChowLT. NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions. Antiviral Res. 2019;170:104559doi:10.1016/j.antiviral.2019.104559http://www.ncbi.nlm.nih.gov/pubmed/31319090
4.
NetchiporoukE.CohenBA. Recognizing and managing eczematous ID reactions to molluscum contagiosum virus in children. Pediatrics. 2012;129(4):e1072-e1075.doi:10.1542/peds.2011-1054http://www.ncbi.nlm.nih.gov/pubmed/22412023
5.
TyringSK.RosenT.BermanBet al. A phase 2 controlled study of SB206, a topical nitric oxide-releasing drug for extragenital wart treatment. J Drugs Dermatol. 2018;17(10):1100-1105.http://www.ncbi.nlm.nih.gov/pubmed/30365591